Bellicum Pharmaceuticals (BLCM) Earnings Date, Estimates & Call Transcripts → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free BLCM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share EarningsStock AnalysisEarningsOwnershipSocial MediaStock AnalysisEarningsOwnershipSocial Media Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueBLCM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BLCM Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. Bellicum Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript11/14/2023Q3 2023-($0.02)($0.02)($0.02)-$1.00 million8/10/2023Q2 2023-($0.24)($0.24)($0.24)--5/11/2023Q1 2023-($0.26)($0.26)($0.26)--11/10/2022Q3 2022-($0.23)($0.23)($0.23)-$1.00 million8/11/2022Q2 2022-($0.13)($0.13)($0.13)--5/12/2022Q1 2022-($0.25)($0.25)($0.25)-- Get the Latest News and Ratings for BLCM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 3/24/2022Q4 2021-($0.27)($0.27)($0.65)-$0.50 million11/4/2021Q3 2021-$0.07+$0.07$0.07-$5.00 million8/11/2021Q2 2021($1.37)($0.22)+$1.15($0.22)-$0.70 million 5/17/2021Q1 2021($1.37)($1.08)+$0.29($0.66)-- Bellicum Pharmaceuticals Earnings - Frequently Asked Questions How much revenue does Bellicum Pharmaceuticals generate each year? Bellicum Pharmaceuticals (NASDAQ:BLCM) has a recorded annual revenue of $1.50 million. How much profit does Bellicum Pharmaceuticals generate each year? Bellicum Pharmaceuticals (NASDAQ:BLCM) has a recorded net income of -$24.97 million. BLCM has generated $0.00 earnings per share over the last four quarters. More Earnings Resources from MarketBeat Related Companies: 9 Meters Biopharma Earnings Results Eiger BioPharmaceuticals Earnings Results Sientra Earnings Results Bellerophon Therapeutics Earnings Results Acorda Therapeutics Earnings Results Evofem Biosciences Earnings Results Aditxt Earnings Results Evelo Biosciences Earnings Results Scinai Immunotherapeutics Earnings Results Neptune Wellness Solutions Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:BLCM) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.